logo

Aptevo Therapeutics Inc (APVO)



Trade APVO now with
  Date
  Headline
5/10/2018 9:02:55 AM Aptevo Therapeutics Posts Q1 Net Loss Of $13.9 Mln Or $0.63/share
5/1/2018 9:04:43 AM Aptevo Therapeutics Announces IND Submission For APVO436
3/13/2018 9:06:21 AM Aptevo Therapeutics 2017 Net Income $7.0 Mln Or $0.33/shr Vs. Loss Of $112.4 Mln Or $5.55/shr Prior Year
1/8/2018 9:07:10 AM Aptevo Therapeutics Begins Patient Dosing In Phase 2 Clinical Evaluation Of Otlertuzumab In New Indication
11/28/2017 7:03:22 AM Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma
8/10/2017 9:04:50 AM Aptevo Therapeutics Q2 Loss Per Share $0.53 Vs Loss $0.63 Last Year